Department of Medicine (DIMED), University of Padova, Padova, Italy.
Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.
Semin Dial. 2021 Nov;34(6):550-560. doi: 10.1111/sdi.12963. Epub 2021 Mar 12.
Extracorporeal blood purification (EBP) techniques provide support for critically ill patients with single or multiple organ dysfunction. Continuous renal replacement therapy (CRRT) is the modality of choice for kidney support for those patients and orchestrates the interactions between the different artificial organ support systems. Intensive care teams should be familiar with the concept of sequential extracorporeal therapy and plan on how to incorporate new treatment modalities into their daily practices. Importantly, scientific evidence should guide the decision-making process at the bedside and provide robust arguments to justify the costs of implementing new EBP treatments. In this narrative review, we explore the extended indications for CRRT as an adjunctive treatment to provide support for the heart, lung, liver, and immune system. We detail practicalities on how to run the treatments and how to tackle the most frequent complications regarding each of the therapies, whether applied alone or integrated. The physicochemical processes and technologies involved at the molecular level encompassing the interactions between the molecules, membranes, and resins are spotlighted. A clinical case will illustrate the timing for the initiation, maintenance, and discontinuation of EBP techniques.
体外血液净化 (EBP) 技术为单一或多器官功能障碍的重症患者提供支持。连续性肾脏替代治疗 (CRRT) 是此类患者肾脏支持的首选方式,协调了不同人工器官支持系统之间的相互作用。重症监护团队应熟悉序贯体外治疗的概念,并计划如何将新的治疗模式纳入日常实践中。重要的是,科学证据应指导床边决策过程,并提供有力的论据来证明实施新的 EBP 治疗的成本是合理的。在这篇叙述性综述中,我们探讨了 CRRT 的扩展适应证,将其作为辅助治疗,为心脏、肺、肝和免疫系统提供支持。我们详细介绍了如何进行治疗的实用性,以及如何解决每种治疗方法(单独应用或整合应用)最常见的并发症。重点介绍了涉及分子间、膜间和树脂间相互作用的分子水平上的理化过程和技术。临床案例将说明 EBP 技术的启动、维持和停止的时间。